Secretory phospholipase: A potential target for cardiovascular therapies

Stephen J. Nicholls, My Ngan Duong

Research output: Contribution to journalArticleResearch


Increasing evidence implicates the activation of inflammatory pathways in the pathogenesis of cardiovascular disease. Accordingly, there is considerable interest in the development of new cardioprotective therapies that target inflammatory factors that promote the progression of heart disease. Secretory phospholipase A2 (sPLA2) generates a range of fatty acid and prostaglandin metabolites that play a pivotal role in the molecular events involved in the formation, progression and rupture of atherosclerotic plaque. The findings of sPLA2 in atherosclerotic plaque, accelerated disease in transgenic models and association between elevated sPLA2 levels in plasma and adverse cardiovascular events in population studies suggest that the pharmacological inhibition of sPLA2 may be beneficial. The early experience with the clinical development of sPLA2 inhibitors to reduce cardiovascular risk will be reviewed.

Original languageEnglish
Pages (from-to)22-26
Number of pages5
JournalHeart and Metabolism
Issue number60
Publication statusPublished - 1 Sep 2013
Externally publishedYes


  • Cardiovascular disease
  • Inflammation
  • Risk factor
  • SPLA

Cite this